Join this session as Ghaith Sankari, Head of Global Digital Health & Data Science, Bayer dives into the practical application of AI in revolutionising drug development and maximizing the value of existing pharmaceutical assets. We will explore a case study demonstrating how AI empowers proactive risk detection across the entire drug lifecycle, from initial target identification to post-market surveillance. Furthermore, Ghaith will showcase how the same AI-driven approach can be leveraged to identify new therapeutic uses for existing drugs.

Key Takeaways:

• Enhanced Business Value through Risk Mitigation: Learn how AI-powered risk detection can minimize losses from failed trials, safety issues, and regulatory delays.
• Accelerated & Cost-Effective Drug Development: Understand how AI-driven drug repurposing can significantly reduce the time and cost of developing new therapies
• Improved Patient Outcomes: Discover how AI-powered drug repurposing can lead to faster access to life-changing therapies for patients